Ben Lichtenstein, president at TradersAudio.com, says investors should focus on "long-sided opportunities" as the U.S. equity market continues to be "on a tear to the upside".» Read More
Marc Ostwald, strategist at Monument Securities, comments on the Bank of England's Inflation Report, saying the bank has a "steady hand" and looks at the breakdown of unemployment "very closely."
Mark Carney, governor of the Bank of England, discusses the impact of the exchange rate on the U.K. recovery.
The U.K. economy continues to face headwinds as the financial sector heals and private and public sector balance sheets continue to be repaired, says Mark Carney, governor of the Bank of England.
Ekaterina Walter, author of "Think Like Zuck", says Facebook's CEO, Mark Zuckerberg possesses the five traits of a very good leader, which include purpose and passion.
Michael Purves, chief global strategist at Weeden & Co., says the U.S. stock market rally should continue as blue chips should drag momentum stocks higher with them.
The electric car championship has secured funding and TV deals across the world ahead of its first season, says Alejandro Agag, CEO of Formula E Holdings.
Kiran Kowshik, currency strategist at BNP Paribas, discusses the U.K. economy following the release of the latest unemployment data.
Pelham Smithers, head of Asian research at Pelham Smithers Associates, says Sony will remain in trouble until it can work out a way to "create an environment" to make its hardware electronics profitable.
CNBC's Catherine Boyle comments on the latest developments in the GSK bribery investigation in China and on the second day of hearings for Pfizer and AstraZeneca's CEOs.
Pascal Soriot, AstraZeneca CEO, says the group has what it takes to succeed on its own and that its "stand-alone strategy" will create value for its shareholders.
AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.
Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.
Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.
Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.
Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.
Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.
Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.
Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."
Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.
Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.
Chatterley is CNBC’s European reporter covering key business and political events, as well as regular Eurogroup and EU leaders summits in Brussels.
Wilfred Frost is anchor of Worldwide Exchange, joining CNBC in 2014.
Seema Mody is a CNBC reporter and host of the "Trading the Twicker" segment on "Fast Money."